Skip to content
Open access

Phase 2 trial to evaluate the safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine (IVT-PCV25) in infants.

Oct 2026 · Vaccine · Vol 94, pp. 129268 · 0 citations · 36 references
Medicine

TL;DR

Although the results suggest that IVT-PCV25 has the potential to broaden serotype coverage, there is scope for formulation optimisation by rebalancing serotype-antigen quantities, and IVT-PCV25 had an acceptable safety profile.

Abstract

INTRODUCTION IVT-PCV25 is a 25-valent pneumococcal conjugate vaccine designed to broaden serotype coverage beyond current vaccines. We evaluated the safety and immunogenicity in infants of three dose-ranging formulations of IVT-PCV25 in comparison to licensed Prevnar-20.

Methods

In this double-blind phase 2 trial in the Philippines, 421 healthy infants were randomly assigned (1:1:1:1) to three IVT-PCV25-formulation arms or a Prevnar-20 arm. Three doses were administered 4-weeks apart from 6 weeks of age, alongside routine vaccinations. Adverse events (AEs), and IgG and functional antibody (opsonophagocytic; OPA) titres were assessed up to 28-days after Dose 3. Unlike IgG concentrations, OPA titres were only measured in a third of the population.

Results

Solicited local and systemic AEs were reported for 90-93% and 94-99% of IVT-PCV25 recipients, respectively, and for 84% and 97% of Prevnar-20 recipients, respectively. These AEs were predominantly mild or moderate, and transient. No serious AE was attributed to IVT-PCV25. All formulations of IVT-PCV25 appeared immunogenic by IgG assay or OPA, or both. IgG GMTs to 19/25 serotype antigens were above the aggregate correlate-of-protection threshold of 0.35 μg/mL; and for the other 6/25 serotypes, the OPA GMTs were > 50-fold the lower limit of quantification (8 dil-1). No clear dose effect was observed. A 2-fold change in antigen quantity only led to a corresponding 2-fold antibody response for four serotypes, and by OPA only. In Prevnar-20 recipients, IgG GMCs were ≥ 0.85 μg/mL for all shared serotypes.

Conclusions

In infants, IVT-PCV25 had an acceptable safety profile. Although the results suggest that IVT-PCV25 has the potential to broaden serotype coverage, there is scope for formulation optimisation by rebalancing serotype-antigen quantities.

Read PDF

Similar papers

Clinical trial Open access Oct 2026

Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials.

BACKGROUND Conventional pneumococcal vaccines cover limited serotypes. This study evaluated the safety and immunogenicity of 24-valent pneumococcal conjugate vaccine (PCV24) in Chinese adults aged ≥18 years. RESEARCH DESIGN AND METHODS Two single-center, randomized, double-blind Phase 1/2 trials were conducted. Two h...

Kang-Ning Wang, Jia-Lei Hu, Hua-Gen Chen et al. · 0 citations
Open access Nov 2026

Immunogenicity and tolerability of a heterologous booster typhoid conjugate vaccine (TCV) five to six years after primary vaccination in Burkinabe Children: An open-label, non-randomized follow-up of a phase 2 trial cohort

Typhoid fever remains a major public health challenge in low- and middle-income countries. In 2018, the World Health Organization recommended a single dose of typhoid conjugate vaccine (TCV) for routine immunization in endemic settings; however, evidence to inform booster dosing remains limited. This study evaluated th...

J. Sawadogo, A. Héma, Diarra Amidou et al. · 0 citations
Clinical trial Open access Oct 2026

Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China

ABSTRACT Co-administration of vaccines targeting multiple respiratory pathogens may enhance coverage and streamline adult immunization programs. We conducted a randomized, multicentre, open-label Phase IV trial registered at Chinese Clinical Trial Registry (ChiCTR2100046227) in China to evaluate the immunogenicity and...

Xuan-Wen Shi, Sha-Sha Han, Cong Wu et al. · 0 citations
Nov 2026

Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.

A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to...

Lionel Martellet, D. Kapse, Prasad S. Kulkarni et al. · 0 citations
Meta-analysis Open access Nov 2026

Comparative safety of the 20-valent and the 13-valent pneumococcal vaccines in infants and toddlers: a systematic review and meta-analysis of randomized trials

ABSTRACT Objective: This systematic review and meta-analysis aimed to compare the safety of the 20-valent pneumococcal conjugate vaccine versus the 13-valent pneumococcal vaccine in healthy infants and toddlers. Data source: We searched PubMed, Scopus, Embase, and Cochrane on January 20, 2026, for randomized controlled...

Helena Beckhäuser Ubaldo, Maria Clara Abreu Vianna Braga, Elisama da Costa Silva et al. · 0 citations
Open access Sep 2026

A phase IV parallel-group, open-label, randomized non-inferiority trial evaluating immunogenicity of extended dosing intervals for Euvichol-S oral cholera vaccine in Nairobi, Kenya: study protocol for a randomized non-inferiority trial

Background Global shortages of oral cholera vaccine have led to widespread use of single-dose vaccination. Although this approach increases immediate population coverage, protection may be less durable and effectiveness is lower in young children. Evidence remains limited on whether extending the interval before the se...

E. Osoro, C. Mbae, K. Doyle et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.